Specifically, the clinical correlation was acceptable in only 13 patients (36.1%), while in 16 patients (44.4%), there was no relationship between IL-6 and tumor progression or pseudoprogression, and the relationship could not be evaluated in 7 patients. This evidence concerns the gene IL6 and neoplasm.